1. Home
  2. MKZR vs MBIO Comparison

MKZR vs MBIO Comparison

Compare MKZR & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MacKenzie Realty Capital Inc.

MKZR

MacKenzie Realty Capital Inc.

N/A

Current Price

$1.38

Market Cap

3.7M

Sector

N/A

ML Signal

N/A

MBIO

Mustang Bio Inc.

BUY

Current Price

$0.48

Market Cap

4.1M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
MKZR
MBIO
Founded
2012
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.1M
IPO Year
2012
2023

Fundamental Metrics

Financial Performance
Metric
MKZR
MBIO
Price
$1.38
$0.48
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.8K
★ 25.4K
Earning Date
09-28-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
48.87
★ 98.99
EPS
N/A
★ N/A
Revenue
★ $20,007,414.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$405.45
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.83
$0.46
52 Week High
$6.00
$1.84

Technical Indicators

Market Signals
Indicator
MKZR
MBIO
Relative Strength Index (RSI) 46.44 33.83
Support Level $1.37 N/A
Resistance Level $1.84 $0.56
Average True Range (ATR) 0.06 0.03
MACD 0.00 -0.00
Stochastic Oscillator 34.78 7.61

Price Performance

Historical Comparison
MKZR
MBIO

About MKZR MacKenzie Realty Capital Inc.

Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: